FR06C0032I1 - - Google Patents

Info

Publication number
FR06C0032I1
FR06C0032I1 FR06C0032C FR06C0032I1 FR 06C0032 I1 FR06C0032 I1 FR 06C0032I1 FR 06C0032 C FR06C0032 C FR 06C0032C FR 06C0032 I1 FR06C0032 I1 FR 06C0032I1
Authority
FR
France
Prior art keywords
pharmaceutical formulations
osteoporosis
useful
concentration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR06C0032I1 publication Critical patent/FR06C0032I1/fr
Application granted granted Critical
Publication of FR06C0032I2 publication Critical patent/FR06C0032I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
FR06C0032C 1998-04-28 2006-10-20 Formulations proteiniques Active FR06C0032I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801495A SE9801495D0 (sv) 1998-04-28 1998-04-28 Protein formulationa
PCT/CA1999/000376 WO1999055353A2 (fr) 1998-04-28 1999-04-26 Formulations proteiniques

Publications (2)

Publication Number Publication Date
FR06C0032I1 true FR06C0032I1 (fr) 2006-11-24
FR06C0032I2 FR06C0032I2 (fr) 2007-04-27

Family

ID=20411122

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0032C Active FR06C0032I2 (fr) 1998-04-28 2006-10-20 Formulations proteiniques

Country Status (24)

Country Link
US (1) US20050209144A1 (fr)
EP (1) EP1079803B1 (fr)
JP (2) JP4733267B2 (fr)
KR (1) KR100579872B1 (fr)
CN (1) CN1172658C (fr)
AT (1) ATE273693T1 (fr)
AU (2) AU766514B2 (fr)
BR (1) BR9909958A (fr)
CA (1) CA2329800C (fr)
CY (1) CY2006006I1 (fr)
DE (3) DE69919533T2 (fr)
DK (1) DK1079803T3 (fr)
ES (1) ES2224637T3 (fr)
FR (1) FR06C0032I2 (fr)
HK (1) HK1041218B (fr)
IL (1) IL139320A (fr)
LU (1) LU91281I2 (fr)
NL (1) NL300243I2 (fr)
NZ (1) NZ508269A (fr)
PT (1) PT1079803E (fr)
SE (1) SE9801495D0 (fr)
SI (1) SI1079803T1 (fr)
WO (1) WO1999055353A2 (fr)
ZA (1) ZA200006040B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
EP1945245A2 (fr) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Parathormone de l'ours noir et procedes d'utilisation de la parathormone de l'ours noir
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CN104645318B (zh) * 2011-06-07 2021-11-02 旭化成制药株式会社 高纯度含pth冷冻干燥制剂及其制造方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
IL307981A (en) 2015-04-29 2023-12-01 Radius Pharmaceuticals Inc Cancer treatment methods
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
CN108333360A (zh) * 2017-01-19 2018-07-27 深圳市新产业生物医学工程股份有限公司 胃泌素释放肽前体稀释液及其应用和试剂盒
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3685849A4 (fr) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation Composition pharmaceutique liquide contenant du tériparatide ayant une excellente stabilité
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
JP2662842B2 (ja) * 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JPH09157294A (ja) * 1995-06-15 1997-06-17 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
JP4053107B2 (ja) * 1996-02-01 2008-02-27 中外製薬株式会社 血小板減少症の予防剤および治療剤
US5964807A (en) * 1996-08-08 1999-10-12 Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa

Also Published As

Publication number Publication date
DE69919533T2 (de) 2005-09-08
NL300243I1 (nl) 2006-12-01
AU766514B2 (en) 2003-10-16
ZA200006040B (en) 2002-01-28
AU2004200156A1 (en) 2004-02-12
SE9801495D0 (sv) 1998-04-28
FR06C0032I2 (fr) 2007-04-27
CY2006006I2 (el) 2009-11-04
CN1319003A (zh) 2001-10-24
DE69919533D1 (de) 2004-09-23
HK1041218B (zh) 2005-03-18
KR20010052276A (ko) 2001-06-25
CA2329800A1 (fr) 1999-11-04
JP4733267B2 (ja) 2011-07-27
CN1172658C (zh) 2004-10-27
DE122006000057I1 (de) 2007-01-04
JP2002512973A (ja) 2002-05-08
CA2329800C (fr) 2004-06-15
JP2011105739A (ja) 2011-06-02
ES2224637T3 (es) 2005-03-01
CY2006006I1 (el) 2009-11-04
KR100579872B1 (ko) 2006-05-12
DK1079803T3 (da) 2004-11-22
IL139320A0 (en) 2001-11-25
IL139320A (en) 2007-06-17
EP1079803B1 (fr) 2004-08-18
EP1079803A2 (fr) 2001-03-07
JP5753692B2 (ja) 2015-07-22
US20050209144A1 (en) 2005-09-22
AU3591699A (en) 1999-11-16
WO1999055353A3 (fr) 2000-01-13
SI1079803T1 (en) 2005-02-28
ATE273693T1 (de) 2004-09-15
HK1041218A1 (en) 2002-07-05
BR9909958A (pt) 2000-12-26
LU91281I2 (fr) 2006-12-19
AU2004200156B2 (en) 2005-12-15
NZ508269A (en) 2003-12-19
WO1999055353A2 (fr) 1999-11-04
DE122006000057I2 (de) 2009-11-05
PT1079803E (pt) 2004-11-30
NL300243I2 (nl) 2007-02-01

Similar Documents

Publication Publication Date Title
FR06C0032I1 (fr)
YU83502A (sh) Nova farmaceutska smeša
BG104727A (en) Pharmaceutical composition of topiramate
BR0008059A (pt) Composições de valdecoxib
MY130727A (en) Controlled-release pharmaceutical formulations
MX9709238A (es) Formulaciones farmaceuticas y de dieta para la profilaxis y tratamiento de trastornos gastrointestinales.
PL309693A1 (en) Combined osteoporosis inhibiting treatment
AP9801269A0 (en) Prostaglandin agonists.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
EP1032556A4 (fr) Composes pharmaceutiquement actifs et procedes d'utilisation
HUP0100024A3 (en) Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
DK1420827T3 (da) 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance
GB9823515D0 (en) Agent for the treatment of osteoporosis
HUP0100634A2 (hu) Pentaeritrit-tetranitrátot tartalmazó gyógyászati készítmények
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих
IT1307866B1 (it) Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption